Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 Cash Ratio is 0.13 as of Feb. 2026, which is 41% below its 10-year median of 0.22. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $51.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 663 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks worse than 84.16% on this metric.
COSMOS Pharmaceutical has a Cash Ratio of 0.13. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for COSMOS Pharmaceutical's Cash Ratio or its related term are showing as below:
CSMYF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.1 Med: 0.22 Max: 0.35
Current: 0.13
During the past 13 years, COSMOS Pharmaceutical's highest Cash Ratio was 0.35. The lowest was 0.10. And the median was 0.22.
CSMYF's Cash Ratio is ranked worse than 84.16% of 663
companies
in the Healthcare Providers & Services industry
Industry Median: 0.59
vs CSMYF: 0.13
COSMOS Pharmaceutical (OTCPK:CSMYF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical Cash Ratio Competitor Comparison
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Cash Ratio distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a Cash Ratio of 0.13 as of Feb. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on COSMOS Pharmaceutical and its competitors. This is 41% below median its historical median of 0.22. Over the past decade, COSMOS Pharmaceutical's Cash Ratio has ranged from 0.10 to 0.35. According to the industry distribution chart, COSMOS Pharmaceutical ranks #558 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 84.2%.
Is COSMOS Pharmaceutical's Cash Ratio too high?
COSMOS Pharmaceutical's current Cash Ratio of 0.13 is 41% below median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.35. The Healthcare Providers & Services industry median Cash Ratio is 0.59. COSMOS Pharmaceutical's value of 0.13 is 78% below this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #558 out of 663 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Cash Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #558 out of 663 companies for Cash Ratio. This places COSMOS Pharmaceutical in the lower half of its industry. The industry median Cash Ratio is 0.59. COSMOS Pharmaceutical's value of 0.13 is 78% below this benchmark. Historically, COSMOS Pharmaceutical's own Cash Ratio has ranged from 0.10 to 0.35 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 0.59, COSMOS Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.59, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current Cash Ratio of 0.13 is 78% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current Cash Ratio is 0.13, which is 41% below median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.79, compared to a current price of $37.06 — trading 28.4% below its estimated fair value. The current Cash Ratio is 0.13, which is 41% below median its 10-year median of 0.22 and 78% below the Healthcare Providers & Services industry median of 0.59. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Cash Ratio is 0.13 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.4% below its estimated GF Value™ of $51.79.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
Cash Ratio: 0.13 (41% below median its 10-year median of 0.22)
GF Value™: $51.79 vs. price of $37.06 (28.4% below fair value)
Industry Position: 78% below the Healthcare Providers & Services median (#558 of 663)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
